Axovant has gained FDA fast track designation for its pipeline drug nelotanserin, a treatment for visual hallucinations suffered by people with dementia with Lewy bodies (DLB).
Axovant Sciences is maintaining its momentum following the appointment of star biotech leader David Hung earlier this week with a new $125 million share offering.
Lexeo Therapeutics' gene therapy for Alzheimer's has shown that it can reduce biomarkers of the disease in a small study, including reductions in disease biomarkers.
